Q-omics provides the consensus-scored ZNF592 profile across patient tissues and cancer cell-line models. ZNF592 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF592 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ZNF592 RNA expression shows 20,114 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ZNF592 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF592 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF592 survival associations across molecular data types. ZNF592 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF592 RNA expression–survival associations across cancer types. High ZNF592 expression shows unfavorable associations in ACC, LUSC and COAD, but favorable associations in KIRC, BRCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF592 RNA expression.
This table summarizes ZNF592 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF592. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF592 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LIHC, STAD and CHOL. The HNSC box plot shows higher ZNF592 RNA expression in tumor versus normal tissue (log2 FC = +0.662, t-test p < 0.001).
This table shows molecular features associated with ZNF592 in patient tissues and cancer cell lines. In patient samples, ZNF592 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF592 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
